<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465878</url>
  </required_header>
  <id_info>
    <org_study_id>16695</org_study_id>
    <secondary_id>I8B-MC-ITSA</secondary_id>
    <secondary_id>2017-003220-78</secondary_id>
    <nct_id>NCT03465878</nct_id>
  </id_info>
  <brief_title>A Study of LY900014 in Participants With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in
      participants with type 1 diabetes mellitus.

      There are 2 parts to this study. Part A is investigating how the body processes LY900014 and
      the effect of LY900014 on blood sugar levels compared to insulin lispro (Humalog) when study
      treatment is given by subcutaneous injection. Part B of the study is investigating how the
      body processes LY900014 and the effect of LY900014 on blood sugar levels compared to insulin
      lispro (Humalog) when study treatment is given by continuous subcutaneous insulin infusion
      (CSII) pump.

      Screening is required within 28 days prior to the start of the study. For each participant,
      the study will last about 40 days in each part.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">March 18, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Insulin Lispro Area Under the Plasma Concentration Curve (AUC) following Each Treatment Arm for Each Study Part</measure>
    <time_frame>Baseline through 7 hours post administration of study drug</time_frame>
    <description>Pharmacokinetics (PK): Insulin Lispro Area Under the Plasma Concentration Curve (AUC) following Each Treatment Arm for Each Study Part</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration versus Time Curve Following each Treatment Arm for Each Study Part</measure>
    <time_frame>Pre dose through 5 hours post administration of study drug</time_frame>
    <description>Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration versus Time Curve Following each Treatment Arm for Each Study Part</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LY900014 Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subcutaneous (SC) dose of LY900014 administered via injection, in one of two study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro (Humalog) SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single, SC dose of insulin lispro (Humalog) administered via injection, in one of two study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, SC bolus dose of LY900014 via continuous subcutaneous insulin infusion (CSII) in one of two study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro (Humalog)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single, SC bolus dose of insulin lispro (Humalog) via CSII in one of two study periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>LY900014 Subcutaneous</arm_group_label>
    <arm_group_label>LY900014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered via SC injection</description>
    <arm_group_label>Insulin Lispro (Humalog) SC</arm_group_label>
    <arm_group_label>Insulin Lispro (Humalog)</arm_group_label>
    <other_name>Humalog</other_name>
    <other_name>LY275585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are male or female participants aged 6-64 with Type 1 Diabetes Mellitus (T1DM) for at
             least 1 year

          -  Have a glycated hemoglobin (HbA1c) less than (&lt;)10.0 percent (%)

        Exclusion Criteria:

          -  Receiving any oral or injectable medication intended for the treatment of diabetes
             mellitus other than insulins in the 12 months prior to screening

          -  More than one episode of severe hypoglycaemia in the last 6 months

          -  Presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or
             gastrointestinal disease, proliferative retinopathy, uncontrolled celiac disease,
             uncontrolled hyperthyroidism or hypothyroidism, or adrenal insufficiency

          -  Have obvious clinical signs or symptoms of liver disease

          -  Have a history of renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontarios</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/type-1-diabetes/ITSA#?postal=</url>
    <description>A Study of LY900014 in Participants With Type 1 Diabetes Mellitus</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

